Eton Pharmaceuticals (ETON) Set to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.05). Eton Pharmaceuticals had a negative return on equity of 6.21% and a negative net margin of 2.96%. The business had revenue of $7.31 million during the quarter, compared to the consensus estimate of $7.70 million.

Eton Pharmaceuticals Stock Down 0.8 %

Shares of Eton Pharmaceuticals stock opened at $3.72 on Wednesday. Eton Pharmaceuticals has a twelve month low of $2.42 and a twelve month high of $5.81. The stock has a market cap of $95.57 million, a price-to-earnings ratio of -124.00 and a beta of 1.19. The company’s fifty day moving average is $3.75 and its 200 day moving average is $4.07.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on shares of Eton Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $8.00 price objective on the stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.